Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

Recruiting

Phase 2

Phase 3

BT8009Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

Sponsor:

BicycleTx Limited

Code:

NCT06225596

Conditions

Metastatic Urothelial Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

BT8009

Pembrolizumab

Gemcitabine + cisplatin Or carboplatin

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-08-25. This information was provided to ClinicalTrials.gov by BicycleTx Limited on 2025-03-28.